	,
	•
	:
	•
_	
_	
_	
	-
7	
=	0
	. `
_	-
_	\mathbf{H}
_	•
_	
	~
_	
	12
_	

Form PTO-1449									DOCKET NO: D-3004	APPLN. NO.: N/A				
IN	FORM	ORMATION DISCLOSURE CITATION					ITAT	ION	APPLICANT: Hughes et al				85 85	
		IN AN APPLICATION (Use several sheets if necessary)							FILING DATE: H r WITH	GROUP ART:	N/A PG			
							U.	S. PATEN	IT DOCUMENTS				10	
EXAMINER INITIAL		DOCUMENT NUMBER DATE						DATE	NAME	SUBCLASS	ING DATE			
														
	· ·												_	
					0						1			
					1									
	<u> </u>			1	•		FORE	IGN PAT	ENT DOCUMENTS					
EXANINE			DOCUL	AENT NU	MBED			DATE		CLASS	SUBCLASS	TRANSLATION		
R			DOCON	ENI NO	MOER				COOMPACE	00.00	0000000	YES	NO	
DS	4	0	1	4	6	7	2	11/14/91	Germany					
1				Ė		<u> </u>	-		20					
						<u> </u>	L					<u></u>		
								OTHER D	OCUMENTS					
B		Tsuzuki et al., "Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug. 2. AZT Derivatives Conjugated with the 1-Adamantane Moiety", journal of Pharm, Sciences, Vol. 83, No. 4, pp. 481-484 (April 1994).												
B		Powell et al., "Chemical and Enzymatic Degradation of Ganciclovir Prodrugs: Enhanced Stability of the Diadamantoate Prodrug Under Acid Conditions", Phar. Research, Vol. 8, No. 11, pp. 1418-1423 (1991).												
1/5	Lagréze et al., "Memantine Is Neuroprotective in a Rat Model of Pressure-Induced Retinal Ischemia", IOVS, Vol. 39, No. 6, pp. 1063-1066 (May 1998).													
1					ď	·								
										·				
EXAMIN	IER	ul	Lis.	(Ŵ	Lc.	K	DATE CONSIDERE	D: 13/00				
EXAMINE				idered,	whether	or not	citation	is in conforman	ce with MPEP § 609; Draw line the	ough citation if	not in conformanc	e and not		

Form \$10-1	149								DOCKET NO: D-300	4	APPLN. NO. 1	0/016	,85
	FORN	OITAI			SUR		TATI	ON	APPLICANT: Hughe	s tal.			
5 2003	<u> </u>				necessa				FILING DATE: 12/14	GROUP ART: 1614			
TRAUE MART							U.	S. PATEN	T DOCUMENTS				
EXAMINER INITIAL			DOCUM	ENT NUN	IBER			DATE	NAME	CLASS	SUBCLASS	RUI	LSING D
INITIAL											1		~
											MA TECH CENT	2	
												+ C/	11
											MA	}	
				<u> </u>		_	_				TECH:	06	200
				<u> </u>	ļ	<u> </u>					JI CENT	10.70	
		 	<u> </u>			├	 				ECH CENT	1, 100	10/2
		<u> </u>	₩.			-	-						
· <u></u>			 	├─								-	
		-	├—	├─								<u> </u>	
	L	L	<u> </u>	<u> </u>		<u> </u>					.1	J	-
	l					<u> </u>	-ORE	1	NT DOCUMENT		T	T	
EXANINER INITIAL			DOCUM	ENT NU	MBEH			DATE	COUNTRY	CLASS	SUBCLASS	YES	TN
175	wo	00/	7	8	3	0	2	12/28/00	International	·			
		····0·······	8	8	5	5	8	-04/04/01	Ецгора		- Contract		
٠,			<u> </u>						-				\perp
				<u> </u>									4
	<u> </u>	<u> </u>	<u> </u>				ļ				<u> </u>		ᆚ
	,							OTHER D	OCUMENTS				
VG									ptide as Effective	e immunoadje	uvant in Ral	obits a	nd
									603-4609.				
05									n Properties, Nu ktrins and Adam				
1									, No. 4, pp. 327				
													н
									*				
		·											
										******		`	
EV 6		<u> </u>							DATE CONCE	CDED.			
EXAMIN	VER /	_	۸.		,			ì	DATE CONSID	EKEU:			
LACIVIII	$\cap H$	Л	1			~		,		4/3/0	- (